Clinical Trials Logo

Neuromuscular Blockade, Residual clinical trials

View clinical trials related to Neuromuscular Blockade, Residual.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06228092 Recruiting - Clinical trials for Neuromuscular Blockade, Residual

Neostigmine/Glyco-pyrrolate 50 Mikrogram/kg or Sugammadex 2 mg/kg for Reversal of Neuromuscular Blockade in Elderly Patients

Start date: December 4, 2023
Phase: Phase 4
Study type: Interventional

The aim of this study is to determine the time to TOF ≥ 0.9 after either neostigmine/glycopyrrolate 50 mikrogr/kg or sugammadex 2 mg/kg in patients with age ≥ 75 years. The hypothesis of this study is that sugammadex 2 mg/kg provides a faster time to TOF ≥ 0.9 compared to neostigmine/glycopyrrolate 50 mikrogr/kg.

NCT ID: NCT06062290 Recruiting - Clinical trials for Postoperative Complications

Does Electromyography Improve Precision and Reliability of Neuromuscular Monitoring in Paediatric Patients

ETCETERA
Start date: September 20, 2023
Phase:
Study type: Observational

Neuromuscular monitoring is used as a standard surveillance method of neuromuscular function to ensure full recovery at the end of anaesthesia. The currently available devices properly provide respective information in adults but not in children. Furthermore, response to neuromuscular blocking agents differs between adults and children due to age-related differences in body composition, physiological function, and acetylcholine receptor density. Recently, electromyographic (EMG) technologies to monitor neuromuscular function were increasingly developed including disposables for nerve stimulation and measurement of the compound muscle action potential in children. However, it is still unclear whether the precision and reliability of these devices is superior to the currently available neuromuscular monitoring for children based on kinemyography (KMG). The ETCETERA study will test the hypothesis that neither EMG nor KMG provides inferior train-of-four readings to the respective reference method in infants and children below five years.